Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Pericardial Fluid Accumulates microRNAs That Regulate Heart Fibrosis after Myocardial Infarction

ED. Silva, D. Pereira-Sousa, F. Ribeiro-Costa, R. Cerqueira, FJ. Enguita, RN. Gomes, J. Dias-Ferreira, C. Pereira, A. Castanheira, P. Pinto-do-Ó, AF. Leite-Moreira, DS. Nascimento

. 2024 ; 25 (15) : . [pub] 20240730

Language English Country Switzerland

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc24019651

Grant support
2022.08730.PTDC Fundação para a Ciência e Tecnologia
POCI-01-0145-FEDER-016385 Fundação para a Ciência e Tecnologia
POCI-01-0145-FEDER-030985 Fundação para a Ciência e Tecnologia
FIS-FIS-2015-01_CCV_20150630- 157 Infarmed

Pericardial fluid (PF) has been suggested as a reservoir of molecular targets that can be modulated for efficient repair after myocardial infarction (MI). Here, we set out to address the content of this biofluid after MI, namely in terms of microRNAs (miRs) that are important modulators of the cardiac pathological response. PF was collected during coronary artery bypass grafting (CABG) from two MI cohorts, patients with non-ST-segment elevation MI (NSTEMI) and patients with ST-segment elevation MI (STEMI), and a control group composed of patients with stable angina and without previous history of MI. The PF miR content was analyzed by small RNA sequencing, and its biological effect was assessed on human cardiac fibroblasts. PF accumulates fibrotic and inflammatory molecules in STEMI patients, namely causing the soluble suppression of tumorigenicity 2 (ST-2), which inversely correlates with the left ventricle ejection fraction. Although the PF of the three patient groups induce similar levels of fibroblast-to-myofibroblast activation in vitro, RNA sequencing revealed that PF from STEMI patients is particularly enriched not only in pro-fibrotic miRs but also anti-fibrotic miRs. Among those, miR-22-3p was herein found to inhibit TGF-β-induced human cardiac fibroblast activation in vitro. PF constitutes an attractive source for screening diagnostic/prognostic miRs and for unveiling novel therapeutic targets in cardiac fibrosis.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24019651
003      
CZ-PrNML
005      
20241024110701.0
007      
ta
008      
241015s2024 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/ijms25158329 $2 doi
035    __
$a (PubMed)39125899
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Silva, Elsa D $u i3S-Institute for Research and Innovation in Health, University of Porto, 4200-135 Porto, Portugal $u ICBAS-Instituto de Ciências Biomédicas Abel Salazar, University of Porto, 4050-313 Porto, Portugal $u INEB-Instituto Nacional de Engenharia Biomédica, University of Porto, 4200-135 Porto, Portugal
245    10
$a Pericardial Fluid Accumulates microRNAs That Regulate Heart Fibrosis after Myocardial Infarction / $c ED. Silva, D. Pereira-Sousa, F. Ribeiro-Costa, R. Cerqueira, FJ. Enguita, RN. Gomes, J. Dias-Ferreira, C. Pereira, A. Castanheira, P. Pinto-do-Ó, AF. Leite-Moreira, DS. Nascimento
520    9_
$a Pericardial fluid (PF) has been suggested as a reservoir of molecular targets that can be modulated for efficient repair after myocardial infarction (MI). Here, we set out to address the content of this biofluid after MI, namely in terms of microRNAs (miRs) that are important modulators of the cardiac pathological response. PF was collected during coronary artery bypass grafting (CABG) from two MI cohorts, patients with non-ST-segment elevation MI (NSTEMI) and patients with ST-segment elevation MI (STEMI), and a control group composed of patients with stable angina and without previous history of MI. The PF miR content was analyzed by small RNA sequencing, and its biological effect was assessed on human cardiac fibroblasts. PF accumulates fibrotic and inflammatory molecules in STEMI patients, namely causing the soluble suppression of tumorigenicity 2 (ST-2), which inversely correlates with the left ventricle ejection fraction. Although the PF of the three patient groups induce similar levels of fibroblast-to-myofibroblast activation in vitro, RNA sequencing revealed that PF from STEMI patients is particularly enriched not only in pro-fibrotic miRs but also anti-fibrotic miRs. Among those, miR-22-3p was herein found to inhibit TGF-β-induced human cardiac fibroblast activation in vitro. PF constitutes an attractive source for screening diagnostic/prognostic miRs and for unveiling novel therapeutic targets in cardiac fibrosis.
650    _2
$a lidé $7 D006801
650    12
$a mikro RNA $x genetika $x metabolismus $7 D035683
650    12
$a fibróza $7 D005355
650    12
$a infarkt myokardu $x metabolismus $x genetika $x patologie $7 D009203
650    _2
$a mužské pohlaví $7 D008297
650    12
$a perikardiální tekutina $x metabolismus $7 D000069236
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a myokard $x metabolismus $x patologie $7 D009206
650    _2
$a lidé středního věku $7 D008875
650    _2
$a fibroblasty $x metabolismus $7 D005347
650    _2
$a senioři $7 D000368
650    _2
$a transformující růstový faktor beta $x metabolismus $7 D016212
650    _2
$a infarkt myokardu s elevacemi ST úseků $x metabolismus $x patologie $x genetika $7 D000072657
650    _2
$a interleukin-1 receptor-like 1 protein $x metabolismus $x genetika $7 D000072179
655    _2
$a časopisecké články $7 D016428
700    1_
$a Pereira-Sousa, Daniel $u i3S-Institute for Research and Innovation in Health, University of Porto, 4200-135 Porto, Portugal $u ICBAS-Instituto de Ciências Biomédicas Abel Salazar, University of Porto, 4050-313 Porto, Portugal $u Center for Translational Medicine (CTM), International Clinical Research Centre (ICRC), St. Anne's Hospital, 60200 Brno, Czech Republic $u Department of Biomedical Sciences, Faculty of Medicine, Masaryk University, 62500 Brno, Czech Republic $1 https://orcid.org/0000000223344610
700    1_
$a Ribeiro-Costa, Francisco $u i3S-Institute for Research and Innovation in Health, University of Porto, 4200-135 Porto, Portugal $u INEB-Instituto Nacional de Engenharia Biomédica, University of Porto, 4200-135 Porto, Portugal
700    1_
$a Cerqueira, Rui $u Cardiovascular R&D Center, Faculty of Medicine, University of Porto, 4150-180 Porto, Portugal $1 https://orcid.org/0000000244714019
700    1_
$a Enguita, Francisco J $u Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, 1649-028 Lisbon, Portugal $1 https://orcid.org/0000000280728557
700    1_
$a Gomes, Rita N $u i3S-Institute for Research and Innovation in Health, University of Porto, 4200-135 Porto, Portugal $u ICBAS-Instituto de Ciências Biomédicas Abel Salazar, University of Porto, 4050-313 Porto, Portugal $u INEB-Instituto Nacional de Engenharia Biomédica, University of Porto, 4200-135 Porto, Portugal $1 https://orcid.org/0000000342372024
700    1_
$a Dias-Ferreira, João $u i3S-Institute for Research and Innovation in Health, University of Porto, 4200-135 Porto, Portugal $u INEB-Instituto Nacional de Engenharia Biomédica, University of Porto, 4200-135 Porto, Portugal $1 https://orcid.org/0009000977136540
700    1_
$a Pereira, Cassilda $u i3S-Institute for Research and Innovation in Health, University of Porto, 4200-135 Porto, Portugal $u INEB-Instituto Nacional de Engenharia Biomédica, University of Porto, 4200-135 Porto, Portugal $u Center for Translational Health and Medical Biotechnology Research (TBIO)/Health Research Network (RISE-Health), ESS, Polytechnic of Porto, 4200-072 Porto, Portugal $u Chemical and Biomolecular Sciences, School of Health (ESS), Polytechnic of Porto, 4200-465 Porto, Portugal $1 https://orcid.org/0000000155144544
700    1_
$a Castanheira, Ana $u i3S-Institute for Research and Innovation in Health, University of Porto, 4200-135 Porto, Portugal $u INEB-Instituto Nacional de Engenharia Biomédica, University of Porto, 4200-135 Porto, Portugal $u INL-International Iberian Nanotechnology Laboratory, 4715-330 Braga, Portugal
700    1_
$a Pinto-do-Ó, Perpétua $u i3S-Institute for Research and Innovation in Health, University of Porto, 4200-135 Porto, Portugal $u ICBAS-Instituto de Ciências Biomédicas Abel Salazar, University of Porto, 4050-313 Porto, Portugal $u INEB-Instituto Nacional de Engenharia Biomédica, University of Porto, 4200-135 Porto, Portugal
700    1_
$a Leite-Moreira, Adelino F $u Cardiovascular R&D Center, Faculty of Medicine, University of Porto, 4150-180 Porto, Portugal $1 https://orcid.org/0000000178083596
700    1_
$a Nascimento, Diana S $u i3S-Institute for Research and Innovation in Health, University of Porto, 4200-135 Porto, Portugal $u ICBAS-Instituto de Ciências Biomédicas Abel Salazar, University of Porto, 4050-313 Porto, Portugal $u INEB-Instituto Nacional de Engenharia Biomédica, University of Porto, 4200-135 Porto, Portugal $1 https://orcid.org/0000000164024245
773    0_
$w MED00176142 $t International journal of molecular sciences $x 1422-0067 $g Roč. 25, č. 15 (2024)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39125899 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20241015 $b ABA008
991    __
$a 20241024110655 $b ABA008
999    __
$a ok $b bmc $g 2202097 $s 1231624
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 25 $c 15 $e 20240730 $i 1422-0067 $m International journal of molecular sciences $n Int J Mol Sci $x MED00176142
GRA    __
$a 2022.08730.PTDC $p Fundação para a Ciência e Tecnologia
GRA    __
$a POCI-01-0145-FEDER-016385 $p Fundação para a Ciência e Tecnologia
GRA    __
$a POCI-01-0145-FEDER-030985 $p Fundação para a Ciência e Tecnologia
GRA    __
$a FIS-FIS-2015-01_CCV_20150630- 157 $p Infarmed
LZP    __
$a Pubmed-20241015

Find record

Citation metrics

Archiving options